Mankind Pharma
BSE 543904 · ISIN INE634S01028
13 stories, newest first.
- Mankind Pharma reschedules Q2 & H1 FY27 earnings conference call to 05:00 P.M. IST on October 26, 2026
- Mankind Pharma schedules in-person group Analyst / Institutional Investors' Meet on October 27, 2026 in Mumbai
- Mankind Pharma reschedules Q2 & H1 FY27 earnings conference call to 5:00 P.M. IST on October 26, 2026
- Dealing room sources expect strong sequential margin performance from Mankind Pharma with positive news flow likely soon
- ESG rating of '71' assigned by NSE Sustainability Ratings and Analytics for FY26
- Board approves EUR 45Mn infusion into Netherlands arm; 70% stake buy in Armed Cell Therapeutics
- Mankind Pharma to acquire 70% of Belgium's Armed Cell Therapeutics via Dutch arm for EUR 48 million
- Board approves 70% stake in Armed Cell Therapeutics via Netherlands arm
- Mankind Pharma to host Q2 & H1 FY27 earnings conference call on October 26, 2026
- Board meeting on October 26, 2026 to consider and approve unaudited Q2 and H1 results
- Srikanth Chauhan of Kotak Securities recommended buying Mankind Pharma with a technical target of 2,900-3,000 rupees
- Analyst recommended buying Mankind Pharma citing long buildup in derivatives and breakout above resistance
- Statutory Auditors Resign at Material Wholly Owned Subsidiary Following Voluntary Liquidation Start
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.